187 related articles for article (PubMed ID: 34152087)
1. Clinical and cost outcomes following genomics-informed treatment for advanced cancers.
Weymann D; Pollard S; Chan B; Titmuss E; Bohm A; Laskin J; Jones SJM; Pleasance E; Nelson J; Fok A; Lim H; Karsan A; Renouf DJ; Schrader KA; Sun S; Yip S; Schaeffer DF; Marra MA; Regier DA
Cancer Med; 2021 Aug; 10(15):5131-5140. PubMed ID: 34152087
[TBL] [Abstract][Full Text] [Related]
2. Matching methods in precision oncology: An introduction and illustrative example.
Weymann D; Laskin J; Jones SJM; Lim H; Renouf DJ; Roscoe R; Schrader KA; Sun S; Yip S; Marra MA; Regier DA
Mol Genet Genomic Med; 2021 Jan; 9(1):e1554. PubMed ID: 33237632
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs.
Haslem DS; Van Norman SB; Fulde G; Knighton AJ; Belnap T; Butler AM; Rhagunath S; Newman D; Gilbert H; Tudor BP; Lin K; Stone GR; Loughmiller DL; Mishra PJ; Srivastava R; Ford JM; Nadauld LD
J Oncol Pract; 2017 Feb; 13(2):e108-e119. PubMed ID: 27601506
[TBL] [Abstract][Full Text] [Related]
4. Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care.
Weymann D; Laskin J; Jones SJM; Roscoe R; Lim HJ; Renouf DJ; Schrader KA; Sun S; Yip S; Marra MA; Regier DA
J Community Genet; 2022 Oct; 13(5):523-538. PubMed ID: 34843087
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing.
Doble B; John T; Thomas D; Fellowes A; Fox S; Lorgelly P
Lung Cancer; 2017 May; 107():22-35. PubMed ID: 27316470
[TBL] [Abstract][Full Text] [Related]
6. Whole-genome and transcriptome analysis enhances precision cancer treatment options.
Pleasance E; Bohm A; Williamson LM; Nelson JMT; Shen Y; Bonakdar M; Titmuss E; Csizmok V; Wee K; Hosseinzadeh S; Grisdale CJ; Reisle C; Taylor GA; Lewis E; Jones MR; Bleile D; Sadeghi S; Zhang W; Davies A; Pellegrini B; Wong T; Bowlby R; Chan SK; Mungall KL; Chuah E; Mungall AJ; Moore RA; Zhao Y; Deol B; Fisic A; Fok A; Regier DA; Weymann D; Schaeffer DF; Young S; Yip S; Schrader K; Levasseur N; Taylor SK; Feng X; Tinker A; Savage KJ; Chia S; Gelmon K; Sun S; Lim H; Renouf DJ; Jones SJM; Marra MA; Laskin J
Ann Oncol; 2022 Sep; 33(9):939-949. PubMed ID: 35691590
[TBL] [Abstract][Full Text] [Related]
7. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
8. Translating genomics in cancer care.
Bombard Y; Bach PB; Offit K
J Natl Compr Canc Netw; 2013 Nov; 11(11):1343-53. PubMed ID: 24225968
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract][Full Text] [Related]
11. Integrating genomics into clinical oncology: ethical and social challenges from proponents of personalized medicine.
McGowan ML; Settersten RA; Juengst ET; Fishman JR
Urol Oncol; 2014 Feb; 32(2):187-92. PubMed ID: 24445286
[TBL] [Abstract][Full Text] [Related]
12. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.
Radovich M; Kiel PJ; Nance SM; Niland EE; Parsley ME; Ferguson ME; Jiang G; Ammakkanavar NR; Einhorn LH; Cheng L; Nassiri M; Davidson DD; Rushing DA; Loehrer PJ; Pili R; Hanna N; Callaghan JT; Skaar TC; Helft PR; Shahda S; O'Neil BH; Schneider BP
Oncotarget; 2016 Aug; 7(35):56491-56500. PubMed ID: 27447854
[TBL] [Abstract][Full Text] [Related]
13. The future of cancer treatment using precision oncogenomics.
Wartman LD
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610395
[TBL] [Abstract][Full Text] [Related]
14. Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer.
Kehl KL; Riely GJ; Lepisto EM; Lavery JA; Warner JL; LeNoue-Newton ML; Sweeney SM; Rudolph JE; Brown S; Yu C; Bedard PL; Schrag D; Panageas KS;
JAMA Netw Open; 2021 Jul; 4(7):e2117547. PubMed ID: 34309669
[TBL] [Abstract][Full Text] [Related]
15. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting.
Presley CJ; Tang D; Soulos PR; Chiang AC; Longtine JA; Adelson KB; Herbst RS; Zhu W; Nussbaum NC; Sorg RA; Agarwala V; Abernethy AP; Gross CP
JAMA; 2018 Aug; 320(5):469-477. PubMed ID: 30088010
[TBL] [Abstract][Full Text] [Related]
16. Impact of genomic profiling on the treatment and outcomes of patients with advanced gastrointestinal malignancies.
Dhir M; Choudry HA; Holtzman MP; Pingpank JF; Ahrendt SA; Zureikat AH; Hogg ME; Bartlett DL; Zeh HJ; Singhi AD; Bahary N
Cancer Med; 2017 Jan; 6(1):195-206. PubMed ID: 28028924
[TBL] [Abstract][Full Text] [Related]
17. Robotic-assisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(27):1-118. PubMed ID: 23074405
[TBL] [Abstract][Full Text] [Related]
18. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
19. A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy.
Wallbillich JJ; Forde B; Havrilesky LJ; Cohn DE
Gynecol Oncol; 2016 Jul; 142(1):144-149. PubMed ID: 27106017
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]